Rotator Cuff TearPhase 1NCT03068988
Clinical Study on Mesenchymal Stem Cells Used in the Reconstruction Surgery of the Supraspinatus Muscle Lesions
A Phase 1 study testing mesenchymal stem cells and without mesenchymal stem cells in people with Rotator Cuff Tear, run by Hospital Znojmo at 1 site in Czechia.
Trial summary
The prospective randomized clinical study investigating the effect of mesenchymal stem cells on tendon healing. The objective of the study is to demonstrate the effect of concentrated bone marrow stem cells ( MSCs ) to the healing of sutured tendon of the supraspinatus muscle in comparison to the same procedure… Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Rotator Cuff Tear
- What is being tested?
- mesenchymal stem cells and without mesenchymal stem cells
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 50 participants
- Where
- 1 siteCzechia
- Study dates
- 1 Jan 2012to 31 Dec 2021
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- men and women aged 18-60 years
- chronic supraspinatus tendon tear greater than 50% of its width
- no history of trauma to the examined shoulder girdle
- confirmation by the clinical examination and preoperative imaging examination ( MRI arthrography )
- signed informed consent
- minimum preoperative haemoglobin concentration in men 13.8 g / dl, in women 12.1 g / dl
Who cannot join
- previous surgical treatment of the rotator cuff
- cuff tear arthropathy grade 3-5 according to Hamada
- fatty degeneration of the cuff muscle ( Goutallier 3 and 4 )
- atrophy of the supraspinatus muscle according to the Thomazeau classification grade II and III
- retraction of the supraspinatus muscle tendon Patte III
- pregnancy
Show all 24Show fewer
- active infection at the surgical site or elsewhere in the body
- osteomyelitis
- sepsis
- history of diabetes
- steroids use
- chemotherapy
- use of NSAIDs
- radiation
- hepatitis
- HIV
- hemato / oncological diseases
- alcohol abuse
- drug abuse
- cigarettes
- medical condition that affects the growth of bone or connective tissue (osteomalacia or other metabolic bone disease)
- vascular insufficiency
- operated extremity muscle atrophy
- neuromuscular disease
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Mesenchymal Stem Cells in the Reconstruction Surgery of the Supraspinatus Muscle Lesions
The prospective randomized clinical study investigating the effect of mesenchymal stem cells on tendon healing. The objective of the study is to demonstrate the effect of concentrated bone marrow stem cells ( MSCs ) to the healing of sutured tendon of the supraspinatus muscle in comparison to the same procedure performed without MSCs. We have postulated the hypothesis that MSCs enhance the healing of the sutured supraspinatus tendon to its humeral footprint.
Read the detailed description
The prospective randomized study is carried out at orthopaedic and traumatology, haematology and radiology departments. 50 patients were included in the study. Of the 25 patients in both groups, Group I (received the concentrate of marrow MSCs into the tendon- bone contact point at the site of the suture during surgery ) consisted of 7 women and 18 men ( mean age 51,2 years ), Group II ( without the use of MSCs ) consisted of 15 women and 10 men ( mean age 50,5 years ). Selection of patients into both groups was performed using permutation block randomization computer software Random Number Generator Software 7.0. All of radiographs/MRI/CT results were evaluated by an experienced radiologist specialized in musculoskeletal pathologies, that was blinded to the both groups of patients. Before entering the study, patients signed an informed consent created by the Ethical Committee of local hospital and were randomly assigned to one of the treatment possibilities with use of the Random Number Generator Software 7.0 by the method 1:1.
Before the surgical treatment, patients completed a questionnaire with VAS score, ASES score ( American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form ) and the Constant score. Further clinical control with completing these questionnaires is 6 months after surgery, 1 year after surgical treatment, 2, 5 and ten years postoperatively. Two years after the surgery MRI examination of the shoulder joint is performed. All of the outpatient clinical evaluations during the study were performed by the orthopaedic surgeon blinded to the both groups of patients.
The actual therapy was as follows: open surgery was preceded by a standard diagnostic arthroscopy, which was performed from the posterior portal for optics and anterior portal for arthroscopic instruments. The tendons of the rotator cuff were assessed from both sides - intraarticular and subacromial. To evaluate cuff tendon injury perioperatively and to measure the rupture width, a special arthroscopic hook calibrated in 1 mm was used. To evaluate the shape of the rupture, the classification of Ellman - Gartsman was used. Surgical treatment of injured tendons of the rotator cuff was performed in the beach chair position of the patient, by the deltoid muscle split approach. After evaluation of the extent and location of the cuff tendon lesion the aspiration of 10 ml of bone marrow blood was done ( from the humeral head through the same surgical approach ) into a 20 mL syringe prefilled with 0.5 ml of heparin with the Yamshidi needle. Aspiration of the bone marrow was performed by surgeon. From one bone puncture was aspirated maximally 3 ml of marrow blood. Centrifugation of the aspirate in 10 ml test-tube Monovette filled with citrate followed. Selected centrifugation regime consisted of gradient 15 minute centrifugation at 200 g RCF ( relative centrifugal force ). After such a centrifugation the tube contents is divided into three parts. The upper layer consists of the platelet-rich plasma (PRP), the middle layer of the buffy coat with the dominant proportion of leukocytes, and the lower layer is formed by sedimented erythrocytes. Using a sterile laboratory pipette, a collection of the buffy coat was performed. MSCs represented 0.01 to 0.02 % of all nuclear elements of the buffy coat, that is about 10 x 106 / l. The MSCs concentrate ( similar to synovial fluid in consistency and colour ) was impregnated into the collagen patch Hypro-Sorb F ( Otrokovice, Czech Republic ) of dimensions 1x2 cm. The collagen patch as a carrier of the MSCs concentrate was used to ensure its retention in desired place. This material was then inserted between the tendon and bone, into the place of re-fixing of the rotator cuff tendons ( footprint ) before tightening the threads of the anchors. Fixation of the tendon to the bone was made by a double row method with use of absorbable fixation anchors BioComposite Corkscrew ( Arthrex, Munich, Germany ). In all such treated cases the tendon was fixed in place of original attachment without any stress and without the need of abduction of the arm above 60 degrees. All patients underwent Neer acromioplasty for an increase of the subacromial space. This procedure was followed by the standard surgical wound closure in all anatomical layers, sterile dressing of the wound and by applying of the abduction orthosis. All patients were operated by the same orthopaedic surgeon with the same surgical technique. Open surgery instead of arthroscopy was chosen because of the safer fixation of the MSCs carrier under the re-inserted tendon and to reduce the risk of washout of the MSCs concentrate from the carrier during the arthroscopy.
Surgical treatment of patients in Group II was identical as in Group I, except the aspiration of bone marrow from the humeral head and subsequent application of the scaffold saturated with MSCs into the tendon / bone interface.
Abduction fixation lasted for 4 weeks. Passive motion over the horizontal line under the guidance of a physiotherapeutist was initiated the first postoperative day. After removing the fixation, an active rehabilitation began, that is a full range of motion exercises done actively 6 weeks after surgery. Full load was allowed 12 weeks after the surgery.
Outpatient follow-up took place according to the schedule mentioned above. To check the integrity of the tendon at the point of insertion into the greater tuberosity of the humerus, MRI of the shoulder joint was performed 2 years postoperatively. Both, preoperative and postoperative MRI examinations were performed with a 1.5T high-field scanner, in sagittal, coronal, and axial planes, in T1- and T2-weighted fat-saturated sequences ( MRI arthrography using gadollinium as a contrast medium ). All of MRI results were evaluated by an experienced radiologist specialized in musculoskeletal pathologies. He evaluated tendon integrity, presence and localisation of complete retear, tendon and muscle borders, and presence of abnormal artifacts.
The primary hypothesis of this study is that the use of mesenchymal stem cells in the supraspinatus tendon reconstruction surgery will have a positive effect in the assessment of both subjective and objective scoring systems, and also in terms of reducing the number of tendon reruptures compared to the patients population in which mesenchymal stem cells were not used. All data were statistically analyzed with STATISTICA 9.0 programme. To compare the results of the of the VAS score, the Constant score, and the ASES score preoperatively and one year after the surgery Student´s t- test was used, to compare the incidence of reruptures between both groups of patients 2 years postoperatively Chi-square test was used. The significance level was determined at p <0.05. Patients were randomly assigned to one of the treatment possibilities with use of the Random Number Generator Software 7.0 by the method 1:1
- Conditions
- Rotator Cuff Tear
- Being tested
- mesenchymal stem cells, without mesenchymal stem cells
- Keywords
- bone marrow stem cells, rotator cuff lesion
- Medical subject headings
- Rotator Cuff Injuries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
mesenchymal stem cellsBiological
mesenchymal stem cells concentrate into the supraspinatus footprint during the surgery
without mesenchymal stem cellsProcedure or surgery
rotator cuff surgery without mesenchymal stem cells
| Study group | Role | What they receive |
|---|---|---|
| mesenchymal stem cells | Experimental | mesenchymal stem cells concentrate into the supraspinatus footprint during the surgery Receives: Biological: mesenchymal stem cells |
| without mesenchymal stem cells | Placebo comparator | rotator cuff surgery without mesenchymal stem cells Receives: Procedure: without mesenchymal stem cells |
What is being measured
The primary outcome is the main question the study is designed to answer.
The supraspinatus tendon re-rupture rate
presence of the supraspinatus tendon rupture on magnetic resonance imaging evaluated 2 years after the surgery, incidence of rerupture compared between group I- with the use of mesenchymal stem cells and group II- without the use of mesenchymal stem cells
Measured: 2 years postoperatively
Secondary outcomes (3)
visual analogue scale
patients subjectively rate the pain level at 6 grade scale from 0-5 where 0 represents no pain and 5 excruciating pain
Measured: 1 day before the surgery, 6 months postoperatively, 1 year postoperatively, 2 years postoperatively, 5 years postoperatively, 10 years postoperatively
ASES score- American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form
Consists of two parts. The first part features a questionnaire filled in by the patients themselves, and included a visual analogue scale for pain and instability and assessment of ability to perform activities of daily living ( ADL ). The second part, which is completed by a doctor, represents an objective assessment of the conditions, and includes the evaluation of range of motion, specific physical characteristics, strength and stability. Score for the arm was then derived from the visual analogue scale for pain (50%) and the general score for ADL (50%).
Measured: 1 day before the surgery, 6 months postoperatively, 1 year postoperatively, 2 years postoperatively, 5 years postoperatively, 10 years postoperatively
Constant score
Two parts: first- subjective evaluation of ADL ( activities of daily living ) from the patient's perspective, the second part is an objective assessment of range of motion and muscle strength performed by the physician
Measured: 1 day before the surgery, 6 months postoperatively, 1 year postoperatively, 2 years postoperatively, 5 years postoperatively, 10 years postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Mar 2017
- Study start1 Jan 2012
- Primary completion31 Dec 2014
- Study completion31 Dec 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Rotator Cuff TearStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hospital Znojmo
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, MUDr. Petr Šmíd, Hospital Znojmo
- Investigators
- Petr Šmíd, Dr., Principal investigator, General Hospital Znojmo, Czech Republic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03068988
- Sponsor's protocol ID
- 2016/05/25/09
- Status last verified
- Sep 2017
- First submitted
- 20 Feb 2017
- Last updated
- 7 Sep 2017
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Goutallier D, Postel JM, Bernageau J, Lavau L, Voisin MC. Fatty muscle degeneration in cuff ruptures. Pre- and postoperative evaluation by CT scan. Clin Orthop Relat Res. 1994 Jul;(304):78-83.
PubMed 8020238Thomazeau H, Boukobza E, Morcet N, Chaperon J, Langlais F. Prediction of rotator cuff repair results by magnetic resonance imaging. Clin Orthop Relat Res. 1997 Nov;(344):275-83.
PubMed 9372778Patte D. Classification of rotator cuff lesions. Clin Orthop Relat Res. 1990 May;(254):81-6.
PubMed 2323151Richards RR, An KN, Bigliani LU, Friedman RJ, Gartsman GM, Gristina AG, Iannotti JP, Mow VC, Sidles JA, Zuckerman JD. A standardized method for the assessment of shoulder function. J Shoulder Elbow Surg. 1994 Nov;3(6):347-52. doi: 10.1016/S1058-2746(09)80019-0. Epub 2009 Feb 13.
PubMed 22958838Constant CR, Murley AH. A clinical method of functional assessment of the shoulder. Clin Orthop Relat Res. 1987 Jan;(214):160-4.
PubMed 3791738
Study at a glance
From the registry record, last updated by the sponsor on 7 Sep 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mesenchymal Stem Cells in the Reconstruction Surgery of the Supraspinatus Muscle Lesions
- ClinicalTrials.gov ID
- NCT03068988
- Acronym / sponsor ID
- 2016/05/25/09
- Conditions
- Rotator Cuff Tear
- Keywords
- bone marrow stem cells, rotator cuff lesion
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Hospital ZnojmoUniversity, hospital or other
- Study start
- 1 Jan 2012 (actual)
- Primary completion
- 31 Dec 2014 (actual)
- Study completion
- 31 Dec 2021 (estimated)
- First posted
- 3 Mar 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The prospective randomized clinical study investigating the effect of mesenchymal stem cells on tendon healing. The objective of the study is to demonstrate the effect of concentrated bone marrow stem cells ( MSCs ) to the healing of sutured tendon of the supraspinatus muscle in comparison to the same procedure performed without MSCs. We have postulated the hypothesis that MSCs enhance the healing of the sutured supraspinatus tendon to its humeral footprint.
Detailed description
The prospective randomized study is carried out at orthopaedic and traumatology, haematology and radiology departments. 50 patients were included in the study. Of the 25 patients in both groups, Group I (received the concentrate of marrow MSCs into the tendon- bone contact point at the site of the suture during surgery ) consisted of 7 women and 18 men ( mean age 51,2 years ), Group II ( without the use of MSCs ) consisted of 15 women and 10 men ( mean age 50,5 years ). Selection of patients into both groups was performed using permutation block randomization computer software Random Number Generator Software 7.0. All of radiographs/MRI/CT results were evaluated by an experienced radiologist specialized in musculoskeletal pathologies, that was blinded to the both groups of patients. Before entering the study, patients signed an informed consent created by the Ethical Committee of local hospital and were randomly assigned to one of the treatment possibilities with use of the Random Number Generator Software 7.0 by the method 1:1.
Before the surgical treatment, patients completed a questionnaire with VAS score, ASES score ( American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form ) and the Constant score. Further clinical control with completing these questionnaires is 6 months after surgery, 1 year after surgical treatment, 2, 5 and ten years postoperatively. Two years after the surgery MRI examination of the shoulder joint is performed. All of the outpatient clinical evaluations during the study were performed by the orthopaedic surgeon blinded to the both groups of patients.
The actual therapy was as follows: open surgery was preceded by a standard diagnostic arthroscopy, which was performed from the posterior portal for optics and anterior portal for arthroscopic instruments. The tendons of the rotator cuff were assessed from both sides - intraarticular and subacromial. To evaluate cuff tendon injury perioperatively and to measure the rupture width, a special arthroscopic hook calibrated in 1 mm was used. To evaluate the shape of the rupture, the classification of Ellman - Gartsman was used. Surgical treatment of injured tendons of the rotator cuff was performed in the beach chair position of the patient, by the deltoid muscle split approach. After evaluation of the extent and location of the cuff tendon lesion the aspiration of 10 ml of bone marrow blood was done ( from the humeral head through the same surgical approach ) into a 20 mL syringe prefilled with 0.5 ml of heparin with the Yamshidi needle. Aspiration of the bone marrow was performed by surgeon. From one bone puncture was aspirated maximally 3 ml of marrow blood. Centrifugation of the aspirate in 10 ml test-tube Monovette filled with citrate followed. Selected centrifugation regime consisted of gradient 15 minute centrifugation at 200 g RCF ( relative centrifugal force ). After such a centrifugation the tube contents is divided into three parts. The upper layer consists of the platelet-rich plasma (PRP), the middle layer of the buffy coat with the dominant proportion of leukocytes, and the lower layer is formed by sedimented erythrocytes. Using a sterile laboratory pipette, a collection of the buffy coat was performed. MSCs represented 0.01 to 0.02 % of all nuclear elements of the buffy coat, that is about 10 x 106 / l. The MSCs concentrate ( similar to synovial fluid in consistency and colour ) was impregnated into the collagen patch Hypro-Sorb F ( Otrokovice, Czech Republic ) of dimensions 1x2 cm. The collagen patch as a carrier of the MSCs concentrate was used to ensure its retention in desired place. This material was then inserted between the tendon and bone, into the place of re-fixing of the rotator cuff tendons ( footprint ) before tightening the threads of the anchors. Fixation of the tendon to the bone was made by a double row method with use of absorbable fixation anchors BioComposite Corkscrew ( Arthrex, Munich, Germany ). In all such treated cases the tendon was fixed in place of original attachment without any stress and without the need of abduction of the arm above 60 degrees. All patients underwent Neer acromioplasty for an increase of the subacromial space. This procedure was followed by the standard surgical wound closure in all anatomical layers, sterile dressing of the wound and by applying of the abduction orthosis. All patients were operated by the same orthopaedic surgeon with the same surgical technique. Open surgery instead of arthroscopy was chosen because of the safer fixation of the MSCs carrier under the re-inserted tendon and to reduce the risk of washout of the MSCs concentrate from the carrier during the arthroscopy.
Surgical treatment of patients in Group II was identical as in Group I, except the aspiration of bone marrow from the humeral head and subsequent application of the scaffold saturated with MSCs into the tendon / bone interface.
Abduction fixation lasted for 4 weeks. Passive motion over the horizontal line under the guidance of a physiotherapeutist was initiated the first postoperative day. After removing the fixation, an active rehabilitation began, that is a full range of motion exercises done actively 6 weeks after surgery. Full load was allowed 12 weeks after the surgery.
Outpatient follow-up took place according to the schedule mentioned above. To check the integrity of the tendon at the point of insertion into the greater tuberosity of the humerus, MRI of the shoulder joint was performed 2 years postoperatively. Both, preoperative and postoperative MRI examinations were performed with a 1.5T high-field scanner, in sagittal, coronal, and axial planes, in T1- and T2-weighted fat-saturated sequences ( MRI arthrography using gadollinium as a contrast medium ). All of MRI results were evaluated by an experienced radiologist specialized in musculoskeletal pathologies. He evaluated tendon integrity, presence and localisation of complete retear, tendon and muscle borders, and presence of abnormal artifacts.
The primary hypothesis of this study is that the use of mesenchymal stem cells in the supraspinatus tendon reconstruction surgery will have a positive effect in the assessment of both subjective and objective scoring systems, and also in terms of reducing the number of tendon reruptures compared to the patients population in which mesenchymal stem cells were not used. All data were statistically analyzed with STATISTICA 9.0 programme. To compare the results of the of the VAS score, the Constant score, and the ASES score preoperatively and one year after the surgery Student´s t- test was used, to compare the incidence of reruptures between both groups of patients 2 years postoperatively Chi-square test was used. The significance level was determined at p <0.05. Patients were randomly assigned to one of the treatment possibilities with use of the Random Number Generator Software 7.0 by the method 1:1
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| mesenchymal stem cells | Experimental | Biological: mesenchymal stem cellsmesenchymal stem cells concentrate into the supraspinatus footprint during the surgery |
| without mesenchymal stem cells | Placebo comparator | Procedure: without mesenchymal stem cellsrotator cuff surgery without mesenchymal stem cells |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- men and women aged 18-60 years
- chronic supraspinatus tendon tear greater than 50% of its width
- no history of trauma to the examined shoulder girdle
- confirmation by the clinical examination and preoperative imaging examination ( MRI arthrography )
- signed informed consent
Key exclusion criteria (24 listed)
- previous surgical treatment of the rotator cuff
- cuff tear arthropathy grade 3-5 according to Hamada
- fatty degeneration of the cuff muscle ( Goutallier 3 and 4 )
- atrophy of the supraspinatus muscle according to the Thomazeau classification grade II and III
- retraction of the supraspinatus muscle tendon Patte III
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| mesenchymal stem cellsmesenchymal stem cells concentrate into the supraspinatus footprint during the surgery | Biological | mesenchymal stem cells |
| without mesenchymal stem cellsrotator cuff surgery without mesenchymal stem cells | Procedure or surgery | without mesenchymal stem cells |
Primary outcome
The supraspinatus tendon re-rupture rate
Time frame: 2 years postoperatively
presence of the supraspinatus tendon rupture on magnetic resonance imaging evaluated 2 years after the surgery, incidence of rerupture compared between group I- with the use of mesenchymal stem cells and group II- without the use of mesenchymal stem cells
3 secondary outcomes
visual analogue scale
Time frame: 1 day before the surgery, 6 months postoperatively, 1 year postoperatively, 2 years postoperatively, 5 years postoperatively, 10 years postoperatively
ASES score- American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form
Time frame: 1 day before the surgery, 6 months postoperatively, 1 year postoperatively, 2 years postoperatively, 5 years postoperatively, 10 years postoperatively
Constant score
Time frame: 1 day before the surgery, 6 months postoperatively, 1 year postoperatively, 2 years postoperatively, 5 years postoperatively, 10 years postoperatively
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Sep 2017.
- Results publication: PubMed 8020238Goutallier D, Postel JM, Bernageau J, Lavau L, Voisin MC. Fatty muscle degeneration in cuff ruptures. Pre- and postoperative evaluation by CT scan. Clin Orthop Relat Res. 1994 Jul;(304):78-83.
- Results publication: PubMed 9372778Thomazeau H, Boukobza E, Morcet N, Chaperon J, Langlais F. Prediction of rotator cuff repair results by magnetic resonance imaging. Clin Orthop Relat Res. 1997 Nov;(344):275-83.
- Results publication: PubMed 2323151Patte D. Classification of rotator cuff lesions. Clin Orthop Relat Res. 1990 May;(254):81-6.
- Results publication: PubMed 22958838Richards RR, An KN, Bigliani LU, Friedman RJ, Gartsman GM, Gristina AG, Iannotti JP, Mow VC, Sidles JA, Zuckerman JD. A standardized method for the assessment of shoulder function. J Shoulder Elbow Surg. 1994 Nov;3(6):347-52. doi: 10.1016/S1058-2746(09)80019-0. Epub 2009 Feb 13.
- Results publication: PubMed 3791738Constant CR, Murley AH. A clinical method of functional assessment of the shoulder. Clin Orthop Relat Res. 1987 Jan;(214):160-4.
- Individual participant dataSharing planned: No
Related trials for Rotator Cuff Tear
Not yet recruiting
Voll Non-Degradable Shoulder Spacer FIH Study
Massive Rotator Cuff Tears, Massive Rotator Cuff Tear
Active, not recruitingPhase 2
Influence of an Anti-osteoporotic Drug on Healing After Surgical Repair of Chronic Rotator Cuff Lesions of the Shoulder
Orthopedics, Traumatology
Recruiting
SMR Stemless Reverse vs SMR Reverse Shoulder System
Arthroplasty, Replacement
Active, not recruiting
BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears
Rotator Cuff Tears
Active, not recruiting
Lyophilized Platelet-Rich Plasma Lysate vs Dextrose Prolotherapy for Partial Rotator Cuff Tears
Rotator Cuff Tear, Rotator Cuff Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Petr Šmíd, Dr. principal investigator
General Hospital Znojmo, Czech Republic
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing mesenchymal stem cells and without mesenchymal stem cells in people with Rotator Cuff Tear, run by Hospital Znojmo at 1 site in Czechia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 7 Sep 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Czechia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The supraspinatus tendon re-rupture rate (time frame: 2 years postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03068988, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Sep 2017.